Please assess the completion status of the following clinical trial:

Trial Title: Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 2 diabetes~* Diagnosis of chronic kidney disease stage 2 or 3 with an estimated GFR of 30-89 ml/min using the four variable MDRD (Modification of Diet in Renal Disease Study Group) formula~* Presence of microalbuminuria or proteinuria less than 3.5 g/d~* Diagnosis of hyperlipidemia currently treated with a statin drug~Exclusion Criteria:~* Not meeting inclusion criteria~* HDL-C \> 40 mg/dL for men, \> 50 mg/dL for women~* TG (triglycerides) \< 150 mg/dL and \> 800 mg/dL~* Documented intolerance to Niaspan or Aspirin~* Treatment with other lipid-lowering agents (fibrates, BAS \[bile acid sequestrants\], or ezetimibe)~* Elevated transaminases (AST or ALT \>1.3 x ULN)~* Unstable type 2 diabetes (FBG \>200 mg/dL or HbA1c \>9.5%)~* Known seropositivity for Hepatitis B, C, or HIV~* Documented history of malignancy~* Age \< 18 years~* Pregnant women or nursing mothers~* Inability to give informed consent~* Start or change in statin dose \< 2 months ago

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Extended release niacin (Type: ACTIVE_COMPARATOR): Extended release niacin 1500-2000 mg daily versus placebo comparator
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).